Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Osimertinib With Chemotherapy as First-line Therapy for Patients With Locally Advanced or Metastatic Epidermal Growth Factor Receptor (EGFR) Mutation-positive Non-Small Cell Lung Cancer (NSCLC): A Multicentre, Observational Study (FOREFRONT)

NCT06376084 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06376084
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06376084 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Osimertinib With Chemotherapy as First-line Therapy for Patients With Locally Advanced or Metastatic Epidermal Growth Factor Receptor (EGFR) Mutation-positive Non-Small Cell Lung Cancer (NSCLC): A Multicentre, Observational Study (FOREFRONT)
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Active, not recruiting
Start date
July 23, 2024
Completion date
February 28, 2028
Enrollment
532 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bronchial neoplasms, carcinoma, bronchogenic, carcinoma, non-small-cell lung, lung diseases, lung neoplasms, neoplasms, neoplasms by site, respiratory tract diseases, respiratory tract neoplasms, thoracic neoplasms